Europe Pharmaceutical Excipients Market Analysis and Forecast by Size, Share, Growth, Trends 2034

The Europe Pharmaceutical Excipients Market size is expected to reach US$ 4,191.0 Million by 2034 from US$ 2,359.7 Million in 2025. The market is estimated to record a CAGR of 6.7% from 2026 to 2034.

Executive Summary and Europe Pharmaceutical Excipients Market Analysis:

The pharmaceutical excipients market in Europe is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The expanding pharmaceutical industry in the region, supported by strong research and development activities and the presence of leading drug manufacturers. Increasing demand for advanced drug formulations, including controlled-release and biologic drugs, has raised the need for high-quality excipients that improve drug stability, solubility, and bioavailability. Additionally, the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer has boosted pharmaceutical production, increasing the consumption of excipients used as binders, fillers, and coating agents. Europe also benefits from strong regulatory frameworks established by organizations such as the European Medicines Agency, which ensure high standards of drug safety and quality, encouraging innovation in excipient development. Furthermore, the growing adoption of generic drugs and biosimilars in Germany, France, and the UK is increasing the demand for cost-effective formulation ingredients. Technological advancements in excipient functionality, with collaborations between pharmaceutical companies and ingredient manufacturers, are accelerating market expansion.

Europe Pharmaceutical Excipients Market: Strategic Insights

Europe Pharmaceutical Excipients Market Segmentation Analysis:

• By Type, the Europe Pharmaceutical Excipients Market is segmented into Bioresorbable Polymers and Lipids and Liposome Based Formulation, Oleochemicals, Sugars, Cellulose, Starches, Petrochemicals, Plant Proteins Polyols and Cyclodextrins, Inorganic Chemicals, and Others. The Cellulose segment dominated the market in 2025.
• By Oleochemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Fatty Alcohols, Metal Stearates, Glycerin, and Other Oleochemicals. The Fatty Alcohols segment dominated the market in 2025.
• By Sugars For Type, the Europe Pharmaceutical Excipients Market is segmented into Actual Sugars, Sugar Alcohols, and Artificial Sweeteners. The Actual Sugars segment dominated the market in 2025.
• By Cellulose For Type, the Europe Pharmaceutical Excipients Market is segmented into Microcrystalline Cellulose, Cellulose Ethers, and Carboxymethylcellulose and Croscarmellose Sodium. The Microcrystalline Cellulose segment dominated the market in 2025.
• By Starches For Type, the Europe Pharmaceutical Excipients Market is segmented into Modified Starches, Dried Starch, and Converted Starch and Pregelatinized Starch. The Modified Starches segment dominated the market in 2025.
• By Petrochemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Glycols, Povidones, Mineral Hydrocarbons, and Other Petrochemicals. The Glycols segment dominated the market in 2025.
• By Inorganic Chemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Magnesium and Calcium Carbonate, Calcium and Aluminum Phosphate, Silicon Dioxide, Titanium Dioxide, and Other Inorganic Chemicals. The Calcium and Aluminum Phosphate segment dominated the market in 2025.
• By Clinical Indication, the Europe Pharmaceutical Excipients Market is segmented into Cancer, Metabolic, Infectious Disease, Dental, Ophthalmic, Cardiovascular, and Other Clinical Indications. The Cancer segment dominated the market in 2025.
• By Functionality, the Europe Pharmaceutical Excipients Market is segmented into Coloring Agents and Coating Agents, Sweetner and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled Release, Antioxidant and Oil, Tablet Filler and Diluent, Binder and Compression and Granulating Agents, Emulsifiers, Surfactants, and Others. The Tablet Filler and Diluent segment dominated the market in 2025.
• By Surfactants For Functionality, the Europe Pharmaceutical Excipients Market is segmented into Polyoxyethylene Hydrogenated Castor Oil, Polysorbates, Sodium Dodecyl Sulfate, and Other Surfactants. The Polysorbates segment dominated the market in 2025.
• By Application, the Europe Pharmaceutical Excipients Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment dominated the market in 2025.
• By Oral For Application, the Europe Pharmaceutical Excipients Market is segmented into Tablet, Capsule, Liquid, and Others. The Tablet segment dominated the market in 2025.
• By Capsule For Oral, the Europe Pharmaceutical Excipients Market is segmented into Hard Gel and Soft Gel. The Hard Gel segment dominated the market in 2025.
• By End User, the Europe Pharmaceutical Excipients Market is segmented into Pharma Industries, Biopharma Industries, Animal Health, and Other End User. The Pharma Industries segment dominated the market in 2025.

Europe Pharmaceutical Excipients Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Pharmaceutical Excipients Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Pharmaceutical Excipients Market Outlook

Rising research and development investments in novel excipients are transforming the pharmaceutical excipients landscape, as companies and regulators collaborate to introduce innovative inactive ingredients that enhance drug delivery and overcome formulation hurdles. The FDA defines a novel excipient as one not previously used in approved drugs or lacking established use, prompting initiatives such as the Novel Excipient Review Pilot Program launched in 2021 to evaluate safety and suitability through precompetitive toxicology studies. This program exemplifies a shift toward structured research and development, where industry stakeholders invest in nonclinical data to de-risk adoption. A survey of 19 pharmaceutical companies conducted by the IQ Novel Excipient Working Group in 2023, revealed that 13 companies had developed 33 distinct nonclinical programs for novel excipients, covering toxicological assessments and quality evaluations to support broader integration into drug products. d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), approved by the FDA as a safe excipient, has been pivotal in solubilizing taxol and docetaxel in oral formulations, improving bioavailability for low-solubility oncology drugs by acting as both a surfactant and absorption enhancer. Another example involves activated charcoal as an adsorbent in extended-release febuxostat tablets, where research and development efforts demonstrated cost-effective sustained release over 12 hours, reducing dosing frequency and enhancing patient compliance through optimized excipient-drug interactions. These investments are fueled by the need for multifunctional excipients in complex therapies, such as co-processed blends such as F-Melt C and Ludiflash, which streamline orally disintegrating tablet production by improving flow and compaction properties. Studies showed disintegration times under 30 seconds without compromising robustness. By bridging gaps in traditional excipients, these research and development efforts not only expedite drug development but also ensure compatibility with stringent regulatory standards, paving the way for safer, more efficient pharmaceuticals that address unmet clinical needs.

Europe Pharmaceutical Excipients Market Country Insights

By country, the Europe Pharmaceutical Excipients Market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The Rest of Europe held the largest share in 2025.

Norway, Denmark, Sweden, Poland, Switzerland, the Netherlands, and Belgium are among the major countries contributing to the pharmaceutical excipients market in the Rest of Europe. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2025, the pharmaceutical industry research and development in Switzerland spent US$ 10,619.48 million (Euro 9,158 million) and US$ 56,661.96 million (Euro 48,864 million) on pharmaceutical production. As pharmaceutical production increases, demand for pharmaceutical excipients also grows.

The increasing incidence of chronic diseases due to aging is crucial in the growing demand for more effective treatments. According to the WHO, the analysis presented at the 4th All-Russia Forum on Public Health found that non-communicable diseases (NCDs) have an economic, social, and developmental impact on the Russian Federation each year. Furthermore, NCDs are the main cause of death and disability in the country, accounting for 87% of deaths. An average Russian citizen has a 25% chance of dying prematurely (before age 70) from one of the four major NCDs: cancer, diabetes, cardiovascular illnesses, and chronic respiratory diseases.

Europe Pharmaceutical Excipients Market Company Profiles

Some of the key players operating in the market include BASF SE, JRS PHARMA GmbH & Co KG, Roquette Freres SA, Avantor Inc, Archer-Daniels-Midland Co, Evonik Industries AG, Merck KGaA, The Dow Chemical Co, The Lubrizol Corp, Ashland Inc, and MEGGLE GmbH & Co KG.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Pharmaceutical Excipients Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise